SS Innovations Enters Licensing Agreement with Johns Hopkins University Company's flagship SSi Mantra surgical system now installed at the university's Baltimore campus Fort Lauderdale, FL.

SS Innovations Enters Licensing Agreement with

Johns Hopkins University

Company's flagship SSi Mantra surgical

system now installed at the university's Baltimore campus

Fort Lauderdale, FL., October 12, 2023 - News

Direct - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of

innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces

it has entered into an agreement with Johns Hopkins University and has installed its SSi Mantra surgical robotic system at the university's

campus in Baltimore, MD.

Under the terms of the agreement, SS Innovations

has installed one system at the Johns Hopkins Minimally Invasive Surgical Training and Innovation Center (MISTIC), where the next generation

of surgeons and health care providers are trained in the use of the latest technological and procedural medical advancements. SS

Innovations and the MISTIC team will share the benefits of these combined research activities.

Dr. Sudhir Srivastava,

Chairman of the Board and Chief Executive Officer of SS Innovations, said, "We are pleased and proud to announce that SS Innovations'

flagship surgical robotic device, the first device of its kind to be made in India, has been installed at the Johns Hopkins University

marks the beginning of a co-development partnership pact to advance to broader procedural applications of medical robotics. Robotic surgery

offers clear benefits to hospitals, surgeons and patients, with its improved accuracy and reduced risk of pain and infection. Our mission

is to use our SSi Mantra to bring this gold standard of medical care to the vast populations throughout the world who currently lack access

to this type of precision surgery.

is one of the only systems in the world to be distinctly cost-effective with broad-spectrum surgical applications, including cardiovascular,

thoracic, and head and neck surgery. It has been granted regulatory approval in India, the United

Arab Emirates and Guatemala and is clinically validated in more than 40 different types of surgical procedures. We are currently working

to secure regulatory approvals in the United States and Europe in 2024 and 2025."

Innovations' SSi Mantra surgical robotic system will be managed onsite at the Johns Hopkins Hospital and will be operated by the

university's lab teams. The two organizations will also launch a knowledge forum showcasing demonstrations and discussions for the

benefit of the global medical robotics community.

About SS Innovations International, Inc.

International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic

surgery affordable and accessible to a larger part of the global population. SSII's product range includes its proprietary "SSi

Mantra" surgical robotic system, and "SSi Mudra", its wide range of surgical instruments capable of supporting a variety

of surgical procedures including robotic cardiac surgery. SSII's business operations are headquartered in India and SSII has plans

to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more

information, visit SSII's website at ssinnovations.com or LinkedIn for updates.

Supporting advanced, affordable, and accessible

robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic,

head and neck, gynecology, urology, general surgery and more. With its modular robotic arms, 3D 4K vision open-console design and superior

ergonomics, the system engages with the surgical team to improve safety and efficiency during procedures.

The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO), Ministry of Health approvals in the United Arab

Emirates and Guatemala and is clinically validated in India in more than 40 different surgical procedures. The company expects to seek

regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe in 2024 and 2025.

Forward-Looking Statements

release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities

Litigation Reform Act of 1995. The words "anticipate," "assume," "believe," "estimate,"

"expect," "will," "intend," "may," "plan," "project," "should,"

"could," "seek," "designed," "potential," "forecast," "target,"

"objective," "goal," or the negatives of such terms or other similar expressions to identify such forward-looking

statements. These statements relate to future events or SS Innovations International's future financial performance and involve

known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements

to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking

For more information: